Chopra Seema, SenGupta Sandip K, Jain Vanita, Kumar Parveen
Department of Obstetrics & Gynaecology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Oman Med J. 2015 Sep;30(5):320-5. doi: 10.5001/omj.2015.66.
Induction of labor (IOL), using intravenous oxytocin, is the artificial initiation of labor before its spontaneous onset for the purpose of delivery of the fetoplacental unit. Although there are various studies looking at dosages of oxytocin, only a few have addressed the issue of discontinuation of oxytocin in the active stage of labor. Thus, our study was conducted to evaluate the need for continuation versus discontinuation of oxytocin during active labor.
This prospective, randomized controlled trial included 106 women who needed IOL. Oxytocin infusion was initiated at a rate of 3mIU/min and was incremental until 4-6cm cervical dilation. At this point the patients were randomly assigned into one of two groups. In group one, oxytocin was discontinued, and infusion was continued with 0.9% sodium chloride solution. In group two, oxytocin was continued at the same dose until delivery.
The duration of oxytocin infusion was 5.5 hours in the oxytocin discontinuation group and 11.0 hours in oxytocin continuation group (p<0.001). The total dose of oxytocin was significantly higher in group two (6.1 units vs. 16.5 units; p=<0.001). The induction-delivery interval was significantly less in group one (9.1 and 11.2 hours in group one and group two, respectively; p=0.023).
Oxytocin discontinuation in the active stage of labor did not prolong the active stage. The total duration of labor and total oxytocin dose were significantly less in the oxytocin discontinuation group. Our results suggest that oxytocin discontinuation is an alternative and viable option particularly in resource poor and economically challenged settings. It not only reduces the need for intense monitoring and prolonged oxytocin use-associated dangers but reduces the total cost of labor management.
使用静脉注射缩宫素引产是在自然发动分娩前人为启动分娩,以娩出胎儿胎盘单位。尽管有各种关于缩宫素剂量的研究,但只有少数研究涉及分娩活跃期缩宫素的停用问题。因此,我们开展本研究以评估分娩活跃期缩宫素持续使用与停用的必要性。
这项前瞻性随机对照试验纳入了106名需要引产的女性。缩宫素以3mIU/分钟的速度开始输注,并逐渐增加剂量直至宫颈扩张4 - 6厘米。此时,患者被随机分为两组。第一组停用缩宫素,继续输注0.9%氯化钠溶液。第二组以相同剂量继续使用缩宫素直至分娩。
缩宫素停用组缩宫素输注持续时间为5.5小时,缩宫素持续使用组为11.0小时(p<0.001)。第二组缩宫素总剂量显著更高(6.1单位对16.5单位;p =<0.001)。第一组引产至分娩间隔显著更短(第一组和第二组分别为9.1小时和11.2小时;p = 0.023)。
分娩活跃期停用缩宫素并未延长活跃期。缩宫素停用组的总产程和缩宫素总剂量显著更低。我们的结果表明,停用缩宫素是一种替代且可行的选择,特别是在资源匮乏和经济困难的环境中。它不仅减少了密切监测的需求以及与缩宫素长期使用相关的风险,还降低了分娩管理的总成本。